ABSTRACT: The
PREVALENCE, COSTS, AND PROGNOSTIC SIGNIFICANCE
The American College of Cardiology-National Cardiovascular Data Registry and National Heart, Lung and Blood Institute-sponsored WISE (Women's Ischemic Syndrome Evaluation) databases suggest that at least 3 to 4 million women and men with signs/symptoms suggestive of myocardial ischemia have no obstructive CAD. 8, 9 Such individuals incur healthcare costs and disabilities similar to those incurred by many with obstructive CAD, in part because of angina and heart failure (HF) hospitalizations and repeat testing. 8, 10 These cost burdens related to hospitalizations and repeat angiography are confirmed by a European consecutive-patient registry. 11 Cardiovascular disease (CVD) is the leading cause of death in Americans. Although more women than men die annually of CVD, predominantly ischemic heart disease, 12 women presenting with symptoms and signs of myocardial ischemia are more likely to have no obstructive CAD on coronary angiography compared with men in the setting of both chronic and acute coronary syndromes (ACS). 4, 8, 13, 14 Such patients are often reassured but offered no specific management, yet data now document a heightened risk of adverse CVD outcomes compared with age-and sex-matched reference subjects. 2, 10, 15 Almost two thirds of women undergoing clinically indicated coronary angiography for suspected ischemic heart disease in the original cohort of the WISE had IN-OCA. 8, 13 During follow-up, they had an intermediate risk for major adverse cardiac event (MACE; death, nonfatal MI, nonfatal stroke, and HF hospitalization) rate exceeding 2.5% yearly by 5 years, as well as elevated rates of readmission and repeat angiography triggered by symptom burden. 10, 16 At 10 years, CVD death or MI occurred in 6.7% of those with no evident angiographic CAD and in 12.8% among those with nonobstructive CAD. 17 Of note, women with INOCA are ≈4 times more likely than men to be readmitted within 180 days for ACS/chest pain. 16 Large, consecutive-case registry reports have replicated this heightened risk for adverse prognosis and extended the findings to men. 2, 3, 18 Given the increased economic role women play in society, it is imperative to many stakeholders (Health and Human Services, Department of Labor, Department of Defense) that we understand and manage this epidemic to avoid direct and indirect economic burden (missed work, disability, death).
PREDICTORS OF ADVERSE OUTCOMES
Older age, hypertension, diabetes mellitus, and smoking have been associated with increased mortality, whereas sex, hyperlipidemia, family history of premature CAD, or pretest CAD likelihood have not. 19 Risk-adjusted analyses found that nonobstructive CAD conferred increased mortality risk compared with patients with no evident CAD. 19 Chest pain persisting at the 1-year follow-up predicted MACE among those with INOCA in the WISE. 20 Measures of nonobstructive CAD extent and severity (WISE CAD severity score, number of vessels involved, etc) also appear important in prognosis, but these measures are not well developed. 2, 3, 17 A large cohort undergoing coronary computed tomographic angiography, with patients propensity matched for age, CAD risk factors, and "angina typicality," observed elevated death/MI rates in those with nonobstructive CAD versus those with normal angiograms. 21 
PATHOPHYSIOLOGY
Mechanisms contributing to INOCA appear multifactorial and may operate alone or in combination. 22, 23 Although these may include hypertension, severe aortic stenosis, severe anemia, type II MI, shunts, certain drugs, HF or cardiogenic shock, Prinzmetal variant angina (coronary spasm), myocardial diseases (eg, myocarditis), congenital heart disease, coronary anomalies, myocardial bridging, and other causes in an occasional patient, underlying mechanisms and appropriate diagnostic and management strategies in these settings are usually apparent. Accordingly, the remainder of this document focuses on clinical situations in which the pathophysiological mechanism for INOCA remains unclear after initial evaluation.
those with normal-appearing angiograms to those with only coronary microvascular dysfunction. There is limited correlation between anatomic CAD severity and functional impairment, as reflected in the CFR. 28 Patients with low CFR, independent of angiographic severity of obstructive disease, have increased risk for adverse outcomes. For example, diabetic patients without obstructive CAD but with impaired CFR experienced cardiac death rates similar to those for nondiabetic patients with CAD. 29 Prospective studies are needed to assess modifiability of CFR to therapy and its ability to reclassify patients at varying risk across the anatomic spectrum of CAD.
Coronary reactivity testing, usually with adenosine or an analog, is required to diagnose CMD. In the WISE, a CFR, defined as an invasive Doppler time-averaged peak hyperemic coronary flow velocity/resting flow velocity <2.32, best predicted adverse outcomes in women with INOCA, with a 5-year MACE rate of 27% versus 9.3% for those with a CFR ≥2.32 (P=0.01). 30 It is important to note that CFR was a continuous predictor of MACE, similar to blood pressure and low-density lipoprotein cholesterol, rather than having a step-like threshold for normal versus abnormal values. Similar findings (Table  2 ) have been observed in other studies that include noninvasive CFR velocity measurements by transthoracic echo Doppler or absolute measurements (in milliliters per minute per gram of myocardium) by positron emission tomography (PET). 26, 31, 32 The latter study provides the most definitive data on CMD and adverse outcome risk among patients with INOCA. 32 In those with CFR PET <2.0, the MACE (cardiac death, MI, late revascularization, or HF hospitalization) rate was increased at 3 years compared with those with higher CFRs. A CFR of <2 was associated with 7.8% and 5.6% annualized MACE among symptomatic men and women without obstructive CAD versus 3.3% and 1.7%, respectively, for those with CFR ≥2.0. 32 It is interesting that although women make up ≈70% of the INOCA population, 41 increased risk associated with limited CFR does not appear different for women compared with men ( Figure 1) . A recent publication demonstrates that the excess cardiovascular risk in women relative to men is associated with severely impaired CFR, not with obstructive CAD. 42 Age, Sex, and Other Risk Variables
Conditions associated with increased risk for CMD appear similar to those for obstructive CAD and include traditional atherosclerosis risk factors such as aging, hypertension, diabetes mellitus, and dyslipidemia. 43 Aging (see below) leads to increased arterial wall stiffness, medial thickening, and lumen enlargement, resulting in increased pulse pressure and hypertrophy of arteries leading to endothelial dysfunction, dysregulation of ventricular-aortic coupling, and subendocardial hypoperfusion, contributing to CMD. 44 Hypertension is associated with remodeling of small arteries, including coronary arteries, 45 and leads to arteriolar constriction and reduced microvascular density. 46 CMD may also be associated with diabetes mellitus 47 because chronic hyperglycemia reduces endothelium-dependent and -independent coronary vasodilator capacity. 48, 49 Hypercholesterolemia may lead to CMD, 50 but higher high-density lipoprotein cholesterol and lower triglyceride levels are associated with higher microvascular flow.
Although CMD is most prevalent in midlife women, WISE data do not support a role for estrogen deficiency. 51 However, traditional CAD risk factors explained <20% of the variation in CMD in the WISE cohort. 51 Traditional risk factors are not always present in CMD, and novel risk markers such as those associated with inflammation may contribute. 51, 52 There is a correlation between high-sensitivity C-reactive protein and number of ischemic episodes during ambulatory ECG monitoring. 53 C-reactive protein is increased among subjects with microvascular angina compared with control subjects, further supporting a possible role of inflammation and endothelial dysfunction in causing CMD. 54 Patients with increased high-sensitivity C-reactive protein have an attenuated rise in cerebral blood flow in response to acetylcholine. 55, 56 Systemic lupus erythematosus is frequently associated with angina and CMD, 57 whereas prior breast cancer chemotherapy may also be associated with CMD. 58 CFR is reduced among patients with normal or minimally diseased coronary arteries and either systemic lupus erythematosus or rheumatoid arthritis, and prolonged systemic inflammation may also contribute to premature CAD in these patients. 59 
Conduit Vessel Stiffness
Aortic pulse wave velocity with other vessel stiffness indexes explained >50% of CFR variance in a WISE sub- study. 60 Arterial stiffness is known to predict cardiovascular events beyond traditional risk factors. When arterial stiffness indexes were assessed by magnetic resonance imaging, ultrasound, and tonometry in asymptomatic subjects from the community, 61 peripheral and central pulse pressure, augmentation index, carotid-femoral pulse wave velocity, and aortic arch pulse wave velocity all increased with age, but ascending aortic strain and distensibility decreased with age. The best markers of subclinical large artery stiffening were aortic arch distensibility in younger individuals and aortic arch pulse wave velocity after age 50.
61

Atherosclerosis
The pathophysiology of atherosclerosis has shifted from a lipid storage disease with large lipid pool thin fibrous cap atheroma (eg, rupture-vulnerable plaque) and flow-limiting plaque resulting in vessel occlusion to a more chronic inflammatory process interrupted by periods of minor plaque rupture, erosion, and distal embolism. 62 The initial phase begins early in life, as oxidant stress related to various risk conditions (genetic predisposition, elevated blood pressure, diabetes mellitus, low-density lipoprotein cholesterol, environmental factors such as tobacco) activates endothelial cells 
STATE OF THE ART
and probably vascular smooth muscle cells. 62 Bone marrow-derived inflammatory cells (monocytes) join endothelial and smooth muscle cells of the artery wall to initiate and perpetuate a less intensive, chronic inflammatory response, leading to endothelial and vascular smooth muscle dysfunction. Multiple adhesion molecules for leukocytes, chemoattractant cytokines, and activators of leukocyte function actively participate in the atherogenic process. This process is systemic with variable endothelial and vascular smooth muscle dysfunction in all vessels (large and small) and plaque growth, within large and medium-sized arteries, leading to different clinical manifestations of ischemia, depending on the acuity of the process and organs involved. 62 Evidence linking microvascular and inflammatory responses to risk factors indicates that oxidative stress, reduced nitric oxide bioavailability, and endothelial activation are common early features of coronary microvascular responses to atherosclerosis risk factors. 63 Almost all patients with INOCA with chronic angina studied by intravascular ultrasound (IVUS) to date have some coronary atherosclerosis. 22, 64 Given sampling limitations of IVUS as used in these reports, those findings strongly suggest that atherosclerosis is a key mediator of the syndrome. In support of this hypothesis, a greater burden of risk factors is associated with more atherosclerosis, concealed by compensatory positive remodeling, yielding diffuse nonobstructive CAD. 64 Plaque rupture by IVUS was not observed in patients with INOCA from 2 series of patients with chronic angina. 5, 22, 64 Two single-center reports of nonobstructive CAD presenting with ACS suggest that plaque rupture is observed in the minority: 38% of 50 women 6 and 37% of men and women. 5 The former study found that plaque ulceration was also frequent, in addition to late gadolinium enhancement with an ischemic pattern of injury. 6 The latter study found that plaque ruptures frequently appeared in more voluminous plaques with large plaque burden and positive remodeling. 5 
Nonobstructive CAD
Prior work evaluating patients suspected to have myocardial ischemia found that ≈40% of women and 8% of men had nonsignificant CAD (30%-49% stenosis).
14 The CASS registry (Coronary Artery Surgery Study) reported that 39% of women and 11% of men with angina had normal coronary arteries. 65 However, CASS lacked an angiographic core laboratory, and in a sample that was retrospectively reviewed, variation in interpretations of proximal lesions was unacceptably high. 66 Furthermore, it is unclear how many patients were retrospectively entered, enhancing survival bias to limit adverse outcome estimates. 67 More recent analyses have linked angiographic measures of extent of nonobstructive CAD with increased risk for adverse outcomes. These include number of major vessels involved with nonobstructive CAD, 3 WISE-CAD Severity Score, 17 and TIMI (Thrombolysis in Myocardial Infarction) frame counts. 68 In a European consecutivecase registry of patients undergoing clinically indicated coronary angiography, the prevalence of nonobstructive CAD was 65% among women and 32% in men. 2 The American College of Cardiology-National Cardiovascular Data Registry prospective registry of patients undergoing clinically indicated invasive coronary angiography found that the prevalence of nonobstructive CAD was 51% in women and 32% in men. 9 Diffuse nonobstructive CAD is increasingly recognized with the more widespread use of fractional flow reserve, which may be helpful in assessing long moderate lesions. Measures from coronary computed tomographic angiography are also evolving. Except for the variables cited above, the other variables have not been studied in detail, and limited positive findings lack replication in other large cohorts.
Blood Pressure
Thickened and stiffened microvessels have poor autoregulatory capacity, allowing transmission of increased blood pressure to the microvessels. 24 Along with hydrau- Figure 1 . Sex effects on coronary microvascular dysfunction measured by positron emission tomography and adverse outcomes in symptomatic patients without obstructive coronary artery disease.
CFR indicates coronary flow reserve. Data obtained from Murthy et al. 32 lic factors such as blood pressure level, intramural factors such as impaired coronary microvascular density and impaired myocardial perfusion likely contribute to INOCA.
Lipids
Dyslipidemia contributes to, and statin treatment improves, coronary endothelial dysfunction. 69 Additional contributing roles include myocardial ischemia-related steatosis, which appears to be mechanistically linked with impairments in ventricular relaxation in women with CMD evidenced by magnetic resonance spectroscopy. 70 Specifically, women with CMD had higher myocardial triglyceride content (0.83±0.12% versus 0.43±0.06%; P=0.025) and lower diastolic circumferential strain rate (168±12%/s versus 217±15%/s; P=0.012), with myocardial triglyceride content correlating inversely with diastolic circumferential strain rate (r=−0.779, P=0.002), 70 suggesting that CMD triggers a metabolic shift away from free fatty acids, resulting in ectopic fat deposition in cardiomyocytes. Mitochondrial functions, including reactive oxygen species signaling, apoptosis, steroid synthesis, hormonal signaling (mitochondrial estrogen receptor), and sexual dimorphism in the expression of mitochondria-related genes, may be involved. 71 
Obesity, Metabolic Syndrome, and Diabetes Mellitus
Obesity-related hypertension, cardiomyocyte hypertrophy, and impaired cardiac vascular adaptation to metabolic needs are well documented in obesity. Decreased serum adiponectin levels and impaired CFR occur in women with normal epicardial coronary arteries. 72 Insulin resistance is strongly associated with both microvascular and macrovascular coronary disorders and confers high risk for CVD morbidity and mortality (women more than men). 4, 73 Coronary microvascular abnormalities are highly prevalent and worsen with progressive glucose intolerance with or without obstructive CAD, and nonobstructive CAD is highly prevalent in those with diabetes mellitus. 34, 74, 75 Cardiac Autonomic Nervous System
Abnormal cardiac adrenergic nerve function is well documented in patients with INOCA. [76] [77] [78] Among patients experiencing mental stress-induced angina, exposure to cold triggers angina, rest angina, or early morning angina. There is close interplay between the autonomic nervous system and endothelium whereby β-adrenergic receptor activation of vascular smooth muscle cells induces vasodilation, α-adrenergic receptor activation induces vasoconstriction, and muscarinic receptor activation induces vasoconstriction. 79, 80 An abnormal vascular response to acetylcholine may be a sign of defective bioavailable nitric oxide, prostacyclin, or excess endothelium-derived hyperpolarizing factor release, or it could be indicative of increased smooth muscle cell sensitivity to muscarinic stimulation or excessive release of endothelium-derived contracting factor, a finding in HF. 81, 82 Sympathetically mediated effects of mental stress on the coronary microcirculation may also be deleterious. 83 For example, CMD after percutaneous coronary intervention is due to sympathetically mediated vasoconstriction and may be prevented or attenuated by oral pretreatment with an α 1 -adrenergic antagonist. 84 Normally, increased sympathetic activity dilates coronary resistance vessels to increase myocardial blood flow, modulated at least partially by endothelium. 81 
Platelet Dysfunction or Other Coagulopathy
Platelet reactivity, in response to collagen/ADP stimulation, decreases after exercise in patients with angina, positive exercise tests, and smooth coronary arteries (eg, IN-OCA). 85 Flow cytometry measures at rest and exercise 86 in patients with INOCA demonstrated that increases in platelet receptor expression and leukocyte-platelet aggregate formation to ACP were consistently lower after exercise than before. These findings agree with and expand on prior work demonstrating lower whole-blood platelet reactivity to collagen/ADP in patients with INOCA after exercise, in contrast to the absence of change in control subjects and an increase in patients with CAD. 13, 14 Changes in platelet receptor expression and leukocyte-platelet aggregate formation have been reported after exercise in INOCA, 86 and adenosine has been shown to inhibit ADP-and thrombininduced monocyte-platelet aggregates in INOCA. 87 
DIAGNOSIS Invasive Testing
CBF is driven by the pressure difference between the aorta and the capillary bed and modulated further by physical and neural factors that affect the microcirculation. Different microcirculation compartments are influenced by one main physiological mechanism to control their vascular tone with cardiac metabolism as the final determining factor. Measurement of coronary vascular function includes measurements of CBF and epicardial coronary artery diameter with endothelium-dependent probes-acetylcholine, bradykinin, substance-P, l-N G -monomethyl arginine citrate, and shear stress-and predominantly endothelium-independent probes, adenosine and sodium nitroprusside. Doses of test agents and definitions of test findings are summarized in Tables 3 and  4 , respectively, in Figure 2 , and the protocol in Table 5 .
Exercise, pacing-induced tachycardia, cold pressor test, and mental stress have also been used to elicit abnor-malities in CBF. The WISE-CVD (coronary vascular dysfunction) project data suggest a strong correlation between acetylcholine and cold pressor test coronary artery diameter changes in women. 22 Reports from invasive testing >1500 patients indicate an excellent safety record with no deaths and <1% procedure-related adverse experiences such as those observed with coronary angiography.
88-90
Noninvasive Testing
Position Emission Tomography PET is a highly accurate, reproducible, and modifiable procedure providing comprehensive evaluation of CBF, including perfusion, left ventricular function, and CFR. There is a strong association between impaired CFR and impaired left ventricular myocardial relaxation or elevated filling pressures that is strongest among those with cardiac troponin elevations. 91 In a study 32 of chest pain patients without CAD history, PET-assessed rest and post hyperemic flow (adenosine, dobutamine, dipyridamole) identified significant MACE predictors: Duke clinical risk score (hazard ratio, 1.06), left ventricular ejection fraction (10% increase; hazard ratio, 0.56), and CFR (hazard ratio, 0.80 for each 10% increase).
Transthoracic Echo Doppler
In another study of patients with chest pain without obstructive CAD and coronary flow velocity, by pulsed wave Doppler of the left anterior descending coronary artery at rest and after dipyridamole, 26% had coronary flow velocity reserve <2.0. 92 Those with low coronary flow velocity reserve had significantly greater physical limitation and disease perception scores on the Seattle Angina Questionnaire.
Cardiac Magnetic Resonance Imaging
Failure of subendocardial perfusion to increase appropriately in response to stress can be detected by cardiac magnetic resonance imaging among subjects with INO-CA. 93, 94 A semiquantitative approach with measurement of myocardial perfusion reserve index detects CMD in women with INOCA. 95 Those with CMD, by abnormal invasive cardiac resynchronization therapy, had reduced myocardial perfusion reserve index compared with normal women. Because the methodology uses standard equipment and protocol available in tertiary hospitals without radiation, myocardial perfusion reserve index appears useful for the diagnosis and management of INOCA and deserves additional evaluation.
MANAGEMENT
At present, the management strategy for INOCA remains unclear, largely because of the absence of an evidence base needed for guidelines. Figure 3 outlines potential therapies for CMD.
Statins, Angiotensin-Converting Enzyme Inhibitors, and Aspirin
Multiple prior statin trials using IVUS have documented prevention of progression, or even regression, of atherosclerosis in coronary arteries and coronary endothelial or vascular smooth muscle function in subjects with nonobstructive CAD. 96, 97 Statins not only lower cholesterol but also have antiatherosclerotic and anti-inflammatory effects. 98 Data support the use of statins to improve CFR. Fluvastatin alone showed improvement in CFR and even greater improvement in combination with diltiazem. 99 Two small pilot studies have shown that administration of atorvastatin improved CFR after 2 months 100 and 6 months. 101 Angiotensin-converting enzyme inhibi- tors (ACE-I) have been shown to improve exercise tolerance and angina symptoms. 102 In the WISE controlled trial, women who received quinapril had improved CFR after 16 weeks compared with the placebo group. In addition, the experimental group had improvement in angina symptoms as shown by the Seattle Angina Questionnaire. 103 Patients with essential hypertension had marked improved coronary blood flow after 12 months of treatment with perindopril, with regression of periarteriolar fibrosis seen on biopsy. 104 In patients already on an ACE-I, the addition of an aldosterone blocker did not improve endothelial function. 105 In subjects with diabetes mellitus, the addition of spironolactone has been shown to improve coronary microvascular function. 106 The benefit of spironolactone is explained by the fact that mineralocorticoid receptor activation has been shown to cause vascular damage 107 and dysfunction. 108 A statin plus ACE-I (atorvastatin and ramipril) was used in a randomized trial of angina patients with normal coronary angiograms and ischemia during stress testing; at 6 months, the statin/ ACE-I strategy improved Seattle Angina Questionnaire scores and exercise duration compared with placebo. Mechanistically, the combination produced greater increases in brachial artery flow-mediated dilation compared with placebo and reduced extracellular superoxide dismutase. 102 
Antiplatelet Agents
A majority of patients with CMD have endothelial dysfunction, and although angiography shows no significant plaque burden, IVUS has demonstrated coronary atherosclerosis in most patients. 22, 64 Therefore, ACC/American Heart Association chronic stable angina guidelines 109 should be extrapolated to use of antiplatelet agents such as aspirin in patients with evidence of ischemia and no obstructive CAD.
Antianginal Agents
Current approaches to the treatment of CMD (Table 6) include the management of risk factors and use of antianginal and antiatherosclerotic medication and some novel agents. However, current literature has little evidence for effective therapy for CMD for the following 2 reasons: First, studies often include patients with cardiac chest pain that may be attributed to clinical entities other than CMD such as cardiac syndrome X, 111 and second, studies have used various CFR cutoff criteria for CMD because there is no guideline consensus definition thus far. 112 Management of risk factors includes control of diabetes mellitus and hypertension. Therapeutically lowering blood pressure can improve CFR, but excess lowering of diastolic blood pressure attenuates the benefit. 113 The insulin sensitizer metformin has been shown to improve endothelial function. 114 Lifestyle modifications include weight loss, 115 smoking cessation, high-fiber diet, fruit and vegetable consumption, and regular physical activity. [116] [117] [118] Few studies have addressed the use of β-blockers. The existing studies included patients with signs and symptoms of ischemia but without definitive diagno- ACE-I indicates angiotensin-converting enzyme inhibitor; APV, average peak blood flow velocity; BP, blood pressure; CAD, coronary artery disease; CB, coronary blood flow; FFR, fractional flow reserve; HR, heart rate; LAD, left anterior descending; and LVEDP, left ventricular end-diastolic pressure. 
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sis of CMD. β -Blockers reduce myocardial oxygen consumption and increase diastolic filling time. Atenolol has been shown to reduce the number of angina episodes 119 and to improve ischemic threshold.
120
Carvedilol has been shown to improve endothelial function. 121 Another class of vasodilator is calcium channel blockers, which are a reasonable first-line treatment for CMD given the underlying pathophysiology. However, one study of intracoronary diltiazem did not improve CFR in CMD patients but rather had a predominant vasodilatory effect on the epicardial artery. 122 Despite these findings, patients with abnormal vasodilator reserve can have improved symptoms, less nitrate use, and improved exercise tolerance after being treated with verapamil or nifedipine. 123 Nitrates achieve antianginal effect through venodilation to reduce preload; in addition, they may have some coronary vasodilatory effect. The use of nitrates may improve patient symptoms, but there are limited data on their effect on endothelial and microvascular function.
Ranolazine is an antianginal that inhibits the late sodium current and overall reduces intracellular calcium levels in cardiomyocytes, thus leading to improved ventricular relaxation. 124 Results for CMD have been conflicting. One pilot study showed improved symptoms in women with angina and evidence of ischemia but no obstructive CAD, and patients with low CFR demonstrated improved CFR with treatment. 125 A similar-sized study showed some improvement with symptoms but no effect on coronary microvascular function. 126 A recent large randomized trial of a 2-week course of ranolazine versus placebo found no difference in symptoms or myocardial perfusion reserve. 127 Ivabradine reduces heart rate through its effect on I f of the sinoatrial node. In patients with stable CAD, it is found to improve CFR. 128 Another study showed improvement of symptoms but no effect on coronary microvascular function. 126 Ivabradine may have a therapeutic role in CMD patients.
Aminophylline, a nonselective adenosine-receptor antagonist, blocks the mediation of nociception. It is postulated to benefit CMD by attenuating the excess dilation of the microvasculature in a relatively well-perfused area, thus shunting blood to a poorly perfused area. Some improvement in symptoms and exercise capacity was seen with short-term intravenous 129 and oral aminophylline 130 in patients with signs and symptoms of ischemia but normal coronary angiogram.
Fasudil, a rho kinase inhibitor that reduces smooth muscle cell hypercontraction, 131 is being investigated currently and has potential for CMD. It has been shown to be effective for vasospastic angina. Preliminary studies showed that patients pretreated with fasudil did not manifest evidence of ischemia with acetylcholine infusion compared with saline pretreatment. 132 There may be a role for l-arginine supplementation to improve endothelial dysfunction because l-arginine is the precursor of nitric oxide. 133 Two studies have found improvement of CFR after 1-time infusion of l-arginine.
134,135
However, Lerman et al 136 found that after 6-month oral supplementation, there is symptom improvement, decreased endothelin concentration, improvement in CBF, but no improvement in CFR.
Given that impaired cardiac nociception may be involved in CMD, low-dose tricyclic antidepressants can be considered because they are thought to have modulatory effects on norepinephrine uptake and anticholinergic effect that can cause analgesia. Imipramine has been shown to reduce frequency of pain 137, 138 but in one of the studies did not show any improvement in quality of life, 138 likely because of its significant side effects.
Nonpharmacological treatments can be effective in controlling patient symptoms. Spinal cord stimulation has been shown to normalize abnormal pain perception, 139 to improve angina symptoms, and to increase exercise tolerance. 140 Enhanced external counterpulsation uses pneumatic cuffs applied to the patient's legs. Sequential inflation and deflation synchronized to the cardiac cycle improves hemodynamics. 141 It has been shown to improve angina in a small case series. 142 Cognitive behavioral therapy can reduce symptom severity and frequency. 143 Cardiac rehabilitation involves multiple sessions of cardiovascular exercise, psychological counseling, and nutritional planning and can be helpful in that it improves blood pressure, body mass index, and exercise capacity. 144 In summary, small studies support the use of statins and ACE-Is to prevent the progression of nonobstructive coronary atherosclerosis and to improve endothelial and microvascular function and symptoms. However, treatments for INOCA have not been studied in clinical outcome trials adequately powered to inform evidencebased guidelines.
KNOWLEDGE GAPS Definition
Gaps in current knowledge related to patient phenotype(s), mechanistic understanding, and management of patients with INOCA are numerous. To advance this field, it is essential to develop a uniform definition of the patient with INOCA. Prevailing elements of a definition, summarized from presentations by Think Tank members, include patients with the following:
1. Stable, chronic (several weeks or longer) symptoms suggesting ischemic heart disease such as chest discomfort with both classic (eg, angina pectoris) and atypical features in terms of location, quality, and inciting factors; 2. Objective evidence for myocardial ischemia from the ECG or a cardiac imaging study (echocardiography, nuclear imaging, magnetic resonance imaging, or spectroscopy) at rest or during stress (exercise, mental, or pharmacological); and 3. Absence of flow-limiting obstruction by coronary angiography (invasive or computed tomographic angiography) as defined by any epicardial coronary artery diameter reduction ≥50% or fractional flow reserve <0.8.
Diagnosis and Phenotyping
Given the likelihood that multiple mechanisms may contribute to INOCA, improved understanding by specific phenotyping of these individuals beyond symptoms and ischemia is needed. For example, although epicardial coronary spasm has been recognized for decades, its specific role in patients with INOCA is unclear. Although recent data suggest that ≈5% of clinically stable women with angina and INOCA have epicardial spasm with intracoronary acetylcholine testing, the role of microvascular coronary spasm requires additional study. but they need to be addressed if we are to make progress in understanding and managing this common syndrome that is increasing in prevalence and costs.
RESEARCH AGENDA FOR THE NEXT DECADE
The following recommendations address 3 overarching goals: to formulate phenotypic classification of patients with INOCA based on clinical presentation, pathophysiological mechanisms, and prognosis; to develop diagnostic algorithms based on this classification system; and to develop management approaches to reduce or prevent symptoms and to modify risk for adverse outcomes. ACEi indicates angiotensin-converting enzyme inhibitor; ASA, aspirin; CAD, coronary artery disease; CMD, coronary microvascular dysfunction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; IHD, ischemic heart disease; MACE, major adverse cardiac event; MRI, magnetic resonance imaging; Rx, prescription; and PET, positron emission tomography.
hospitalization) and will be useful for predicting risk and directing new therapies. 
CONCLUSIONS
The prevalence of nonobstructive CAD among clinically ordered coronary angiograms conducted for evidence of suspected myocardial ischemia (INOCA) is increasing. [1] [2] [3] [4] A subgroup of these patients has CMD, an elevated risk for a cardiovascular event (including ACS and repeat cardiovascular procedures), and higher risk for the development of HF hospitalization. At present, there is no uniform, comprehensive diagnostic strategy or algorithm for risk stratification for these patients; however, invasive and noninvasive CFR testing can be useful. Although small trials have suggested benefit from ACE-Is and statins, there is a lack of appropriately designed clinical outcome trials to inform evidence-based therapeutic strategies. Next steps needed to address knowledge gaps include evidence-based approaches to the definition, diagnostic evaluation, risk stratification, and management of patients with INOCA, including large outcome clinical trials. This summary of our current understanding of INOCA (Figure 4) supports the need for a research agenda for the next decade to facilitate the development of evidence-based risk assessment tools and effective therapies for this rapidly growing patient population.
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